Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOTRIMIN AF vs AUKELSO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Selective inhibitor of the mammalian target of rapamycin (m TOR) kinase, specifically the m TORC1 complex, leading to inhibition of cell proliferation, angiogenesis, and glucose uptake.
Tinea pedis,Tinea cruris,Tinea corporis,Pityriasis versicolor,Cutaneous candidiasis
Advanced renal cell carcinoma,Progressive neuroendocrine tumors of pancreatic origin,Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis,Advanced neuroendocrine tumors of gastrointestinal or lung origin
Topical: Apply twice daily (morning and evening) to affected area for 2-4 weeks. Intravaginal: One 200 mg suppository vaginally at bedtime for 3 days, or one 500 mg vaginal tablet as a single dose.
400 mg orally twice daily with food.
Terminal elimination half-life of absorbed clotrimazole is approximately 3.5–4 hours, but this is clinically irrelevant due to negligible systemic absorption after topical application.
Terminal elimination half-life approximately 24 hours (range 20–28 h), supports once-daily dosing; prolonged in severe hepatic impairment.
Minimal systemic absorption; primarily local metabolism.
Primarily metabolized by CYP3A4
Less than 1% of topical clotrimazole is absorbed; absorbed drug is metabolized in the liver to inactive metabolites and excreted primarily in feces (approximately 69%) and urine (approximately 21%) via biliary and renal routes.
Primarily hepatic metabolism with biliary excretion; ~20% renal elimination of unchanged drug. Fecal excretion of metabolites accounts for ~65% of total clearance.
Approximately 90–95% bound to plasma proteins, primarily albumin.
High protein binding, approximately 99.8%, primarily to albumin and alpha-1-acid glycoprotein.
Vd is approximately 2.5 L/kg after intravenous administration (data for systemic formulation); after topical application, systemic absorption is negligible (<1%), so Vd is not clinically meaningful.
Volume of distribution ~0.15 L/kg (range 0.12–0.18 L/kg), indicating limited extravascular distribution, predominantly confined to plasma and extracellular fluid.
Topical: Systemic bioavailability is <1% after application to intact skin; vaginal tablet: approximately 3–10% absorbed systemically.
Oral bioavailability ~85%; unaffected by food.
No dosage adjustment required for renal impairment.
GFR ≥60 m L/min: no adjustment; GFR 30-59 m L/min: 200 mg twice daily; GFR <30 m L/min: 200 mg once daily; hemodialysis: 200 mg three times weekly after dialysis.
No dosage adjustment required for hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg twice daily; Child-Pugh C: 200 mg once daily.
Children ≥2 years: Same as adult dosing for topical application. Children <2 years: Not recommended without physician consultation.
Body weight 10-20 kg: 200 mg twice daily; 20-40 kg: 300 mg twice daily; ≥40 kg: 400 mg twice daily.
No specific dose adjustment; use same adult dosing with consideration of renal/hepatic function and potential drug interactions.
No specific dose adjustment based on age alone; monitor renal function and adjust per renal guidelines.
None
No FDA black box warning.
For external use only,Avoid contact with eyes,Discontinue if irritation occurs,Not for vaginal or oral use
Non-infectious pneumonitis,Infections (including opportunistic infections),Hypersensitivity reactions,Renal impairment,Metabolic effects (hyperglycemia, hyperlipidemia),Interstitial lung disease,Hemorrhagic events,Wound healing complications,Immunosuppression,Increased risk of thrombosis
Hypersensitivity to clotrimazole or any component
Hypersensitivity to everolimus or any component of the formulation
No clinically significant food interactions for topical clotrimazole.
Avoid grapefruit and grapefruit juice; may increase drug levels. Take with or without food, but high-fat meals may increase absorption. Avoid alcohol due to hepatotoxicity risk.
Clotrimazole (Lotrimin AF) is category B. No evidence of teratogenicity in animal studies. Limited human data from topical use in first trimester show no increased risk of major malformations. Systemic absorption from topical application is minimal (<0.5%), making fetal exposure negligible. No known fetal risks from topical use in any trimester.
First trimester: Avoid use due to potential for fetal harm based on animal studies showing developmental toxicity (including cardiovascular and skeletal malformations). Second and third trimesters: Use only if maternal benefit outweighs fetal risk; may cause fetal growth restriction or oligohydramnios in off-label experience. No adequate human data.
Topical clotrimazole is considered compatible with breastfeeding. Systemic absorption is minimal, and any excreted amounts in breast milk are negligible. M/P ratio is not available due to minimal absorption. Avoid application to breast area to prevent infant oral contact.
No human data on milk excretion or infant effects. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., immunosuppression), advise against breastfeeding during treatment and for 2 weeks after last dose.
No dose adjustment required for topical clotrimazole during pregnancy. Pharmacokinetics are not significantly altered as systemic absorption is minimal. Use standard dosing for indication (e.g., 1% cream twice daily for 2-4 weeks for dermatophytosis).
No established dose adjustment in pregnancy. Consider reduced dosing if increased clearance occurs (second trimester). Monitor drug levels if available; otherwise, adjust based on clinical response and toxicity.
Lotrimin AF (clotrimazole) is a topical antifungal used for dermatophyte and yeast infections. For tinea pedis, apply twice daily for 4 weeks; shorter courses may lead to recurrence. Do not use in or near eyes. Avoid occlusive dressings unless directed.
Monitor for QT prolongation, electrolyte abnormalities, and hepatotoxicity. Adjust dose in renal impairment (Cr Cl <30 m L/min). Avoid use with strong CYP3A4 inhibitors or inducers. Note potential for phototoxicity; advise sun avoidance.
Apply a thin layer to affected skin twice daily, morning and evening.,Wash hands before and after application unless treating hands.,Continue use for the full prescribed duration even if symptoms improve.,Avoid contact with eyes, mouth, or open wounds.,Do not cover treated area with bandages or plastic unless instructed.
Take exactly as prescribed; do not change dose or stop without consulting doctor.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception during therapy and for 1 month after last dose.,Report symptoms like irregular heartbeat, fainting, severe nausea/vomiting, or yellowing of skin/eyes immediately.,Use sunscreen and protective clothing; avoid sun exposure, even through glass.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOTRIMIN AF vs AUKELSO, answered by our medical review team.
LOTRIMIN AF is a Topical Antifungal that works by Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.. AUKELSO is a Topical Antifungal that works by Selective inhibitor of the mammalian target of rapamycin (m TOR) kinase, specifically the m TORC1 complex, leading to inhibition of cell proliferation, angiogenesis, and glucose uptake.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOTRIMIN AF and AUKELSO depend on the specific clinical indication. These are both Topical Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOTRIMIN AF is: Topical: Apply twice daily (morning and evening) to affected area for 2-4 weeks. Intravaginal: One 200 mg suppository vaginally at bedtime for 3 days, or one 500 mg vaginal tablet as a single dose.. The standard adult dose of AUKELSO is: 400 mg orally twice daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOTRIMIN AF and AUKELSO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOTRIMIN AF is classified as Category C. Clotrimazole (Lotrimin AF) is category B. No evidence of teratogenicity in animal studies. Limited human data from topical use in first trimester show no increased risk of major ma. AUKELSO is classified as Category C. First trimester: Avoid use due to potential for fetal harm based on animal studies showing developmental toxicity (including cardiovascular and skeletal malformations). Second and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.